Clinical utility of targeted treatments in the management of epithelial ovarian cancer

References

• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• ParkinDMBrayFFerlayJPisaniPGlobal cancer statistics, 2002CA Cancer J Clin20055527410815761078
   PubMed Web of Science ®Google Scholar
• SankaranarayananRFerlayJWorldwide burden of gynaecological cancer: the size of the problemBest Pract Res Clin Obstet Gynaecol200620220722516359925
   PubMed Web of Science ®Google Scholar
• WakabayashiMTLinPSHakimAAThe role of cytoreductive/debulking surgery in ovarian cancerJ Natl Compr Canc Netw20086880381018926091
   PubMedGoogle Scholar
• BristowRETomacruzRSArmstrongDKTrimbleELMontzFJSurvival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysisJ Clin Oncol20022051248125911870167
   PubMed Web of Science ®Google Scholar
• OzolsRFBundyBNGreerBEPhase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol200321173194320012860964
   PubMed Web of Science ®Google Scholar
• VergoteITropeCGAmantFNeoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancerN Engl J Med20103631094395320818904
   PubMed Web of Science ®Google Scholar
• DiSaiaPJCreasmanWTEpithelial ovarian cancerClinical Gynecologic Oncology7th edSt Louis, MOMosby Elsevier2007
   Google Scholar
• YapTACardenCPKayeSBBeyond chemotherapy: targeted therapies in ovarian cancerNat Rev Cancer20099316718119238149
   PubMed Web of Science ®Google Scholar
• BurgerRASillMWMonkBJGreerBESoroskyJIPhase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyJ Clin Oncol200725335165517118024863
   PubMed Web of Science ®Google Scholar
• CannistraSAMatulonisUAPensonRTPhase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerJ Clin Oncol200725335180518618024865
   PubMed Web of Science ®Google Scholar
• NimeiriHSOzaAMMorganRJEfficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II ConsortiaGynecol Oncol20081101495518423560
   PubMed Web of Science ®Google Scholar
• AghajanianCFinklerNJRutherfordTOCEANS: A randomized, double-blinded, placebo-controlled Phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)J Clin Oncol201129Suppl Abstr LBA5007
   Google Scholar
• EbosJMLeeCRCruz-MunozWBjarnasonGAChristensenJGKerbelRSAccelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesisCancer Cell200915323223919249681
   PubMed Web of Science ®Google Scholar
• Paez-RibesMAllenEHudockJAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisCancer Cell200915322023119249680
   PubMed Web of Science ®Google Scholar
• TewWPColomboNRay-CoquardIVEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter Phase II studyJ Clin Oncol20072518S5508
   Google Scholar
• GotliebWHAmantFAdvaniSIntravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a Phase 2, randomised, double-blind, placebo-controlled studyLancet Oncol201213215416222192729
   PubMed Web of Science ®Google Scholar
• MateiDSillMWLankesHAActivity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trialJ Clin Oncol2011291697521098323
   PubMed Web of Science ®Google Scholar
• WelchSAHirteHWElitLSorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II ConsortiumInt J Gynecol Cancer201020578779320847613
   PubMed Web of Science ®Google Scholar
• BiagiJJOzaAMChalchalHIA Phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group StudyAnn Oncol201122233534020705911
   PubMed Web of Science ®Google Scholar
• MatulonisUABerlinSIvyPCediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancerJ Clin Oncol200927335601560619826113
   PubMed Web of Science ®Google Scholar
• RajaFAGriffinCLQianWInitial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancerBr J Cancer2011105788488921878941
   PubMed Web of Science ®Google Scholar
• HerbstRSHongDChapLSafety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumorsJ Clin Oncol200927213557356519546406
   PubMed Web of Science ®Google Scholar
• HilbergFRothGJKrssakMBIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacyCancer Res200868124774478218559524
   PubMed Web of Science ®Google Scholar
• MarshallJClinical implications of the mechanism of epidermal growth factor receptor inhibitorsCancer200610761207121816909423
   PubMed Web of Science ®Google Scholar
• GordonANFinklerNEdwardsRPEfficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a Phase II multicenter studyInt J Gynecol Cancer200515578579216174225
   PubMed Web of Science ®Google Scholar
• PosadasEMKwitkowskiVKotzHLA prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a Phase II clinical study with proteomic profilingCancer2007110230931717559139
   PubMed Web of Science ®Google Scholar
• SchilderRJSillMWChenXPhase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group studyClin Cancer Res200511155539554816061871
   PubMed Web of Science ®Google Scholar
• PosadasEMLielMSKwitkowskiVA Phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancerCancer200710971323133017330838
   PubMed Web of Science ®Google Scholar
• HirteHOzaASwenertonKA Phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)Gynecol Oncol2010118330831220646751
   PubMed Web of Science ®Google Scholar
• PautierPJolyFKerbratPPhase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)Gynecol Oncol2010116215716220109725
   PubMed Web of Science ®Google Scholar
• SchilderRJPathakHBLokshinAEPhase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rashGynecol Oncol20091131212719162309
   PubMed Web of Science ®Google Scholar
• SecordAABlessingJAArmstrongDKPhase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group studyGynecol Oncol2008108349349918191993
   PubMed Web of Science ®Google Scholar
• SeidenMVBurrisHAMatulonisUA Phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignanciesGynecol Oncol2007104372773117126894
   PubMed Web of Science ®Google Scholar
• GordonMSMateiDAghajanianCClinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusJ Clin Oncol200624264324433216896006
   PubMed Web of Science ®Google Scholar
• MakhijaSAmlerLCGlennDClinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancerJ Clin Oncol20102871215122319901115
   PubMed Web of Science ®Google Scholar
• HenriksenRFunaKWilanderEBackstromTRidderheimMObergKExpression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasmsCancer Res19935319455045548402626
   PubMed Web of Science ®Google Scholar
• MateiDEmersonRELaiYCAutocrine activation of PDG-FRalpha promotes the progression of ovarian cancerOncogene200625142060206916331269
   PubMed Web of Science ®Google Scholar
• RazaAFranklinMJDudekAZPericytes and vessel maturation during tumor angiogenesis and metastasisAm J Hematol201085859359820540157
   PubMed Web of Science ®Google Scholar
• LuCKamatAALinYGDual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinomaClin Cancer Res200713144209421717634550
   PubMed Web of Science ®Google Scholar
• LuCShahzadMMMoreno-SmithMTargeting pericytes with a PDGF-B aptamer in human ovarian carcinoma modelsCancer Biol Ther20109317618220009575
   PubMed Web of Science ®Google Scholar
• HeinrichMCBlankeCDDrukerBJCorlessCLInhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignanciesJ Clin Oncol20022061692170311896121
   PubMed Web of Science ®Google Scholar
• AlbertsDSLiuPYWilczynskiSPPhase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)Int J Gynecol Cancer200717478478817343607
   PubMed Web of Science ®Google Scholar
• ColemanRLBroaddusRRBodurkaDCPhase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancersGynecol Oncol2006101112613116271384
   PubMed Web of Science ®Google Scholar
• SchilderRJSillMWLeeRBPhase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group studyJ Clin Oncol200826203418342518612157
   PubMed Web of Science ®Google Scholar
• MateiDEmersonRESchilderJImatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trialCancer2008113472373218618737
   PubMed Web of Science ®Google Scholar
• SafraTAndreopoulouELevinsonBWeekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancerAnticancer Res20103093243324720944093
   PubMed Web of Science ®Google Scholar
• JavleMCurtinNJThe role of PARP in DNA repair and its therapeutic exploitationBr J Cancer201110581114112221989215
   PubMed Web of Science ®Google Scholar
• WeberpalsJIClark-KnowlesKVVanderhydenBCSporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathwayJ Clin Oncol200826193259326718591560
   PubMed Web of Science ®Google Scholar
• FongPCBossDSYapTAInhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersN Engl J Med2009361212313419553641
   PubMed Web of Science ®Google Scholar
• FongPCYapTABossDSPoly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalJ Clin Oncol201028152512251920406929
   PubMed Web of Science ®Google Scholar
• AudehMWCarmichaelJPensonRTOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialLancet2010376973724525120609468
   PubMed Web of Science ®Google Scholar
• AdjeiAAPemetrexed: a multitargeted antifolate agent with promising activity in solid tumorsAnn Oncol200011101335134111106124
   PubMed Web of Science ®Google Scholar
• KalliKRObergALKeeneyGLFolate receptor alpha as a tumor target in epithelial ovarian cancerGynecol Oncol2008108361962618222534
   PubMed Web of Science ®Google Scholar
• MarkertSLassmannSGabrielBAlpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissueAnticancer Res2008286A3567357219189636
   PubMed Web of Science ®Google Scholar
• EbelWRouthierELFoleyBPreclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alphaCancer Immun20077617346028
   PubMedGoogle Scholar
• MillerDSBlessingJAKrasnerCNPhase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology GroupJ Clin Oncol200927162686269119332726
   PubMed Web of Science ®Google Scholar
• VergoteICalvertHKaniaMKaiserCZimmermannAHSehouliJA randomised, double-blind, Phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancerEur J Cancer20094581415142319168349
   PubMed Web of Science ®Google Scholar
• MatulonisUAHorowitzNSCamposSMPhase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancerJ Clin Oncol200826355761576619001330
   PubMed Web of Science ®Google Scholar
• KonnerJABell-McGuinnKMSabbatiniPFarletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a Phase I studyClin Cancer Res201016215288529520855460
   PubMed Web of Science ®Google Scholar
• UshaLSillMWDarcyKMA Gynecologic Oncology Group Phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignanciesGynecol Oncol2011121345546121414654
   PubMed Web of Science ®Google Scholar
• BehbakhtKSillMWDarcyKMPhase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group studyGynecol Oncol20111231192621752435
   PubMed Web of Science ®Google Scholar
• HiraiHSootomeHNakatsuruYMK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivoMol Cancer Ther2010971956196720571069
   PubMed Web of Science ®Google Scholar
• SchoeberlBFaberACLiDAn ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationCancer Res20107062485249420215504
   PubMed Web of Science ®Google Scholar
• KatsumataNYasudaMTakahashiFDose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a Phase 3, open-label, randomised controlled trialLancet200937496981331133819767092
   PubMed Web of Science ®Google Scholar
• FujiwaraKAotaniEHamanoTA randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancerJpn J Clin Oncol201141227828220937602
   PubMed Web of Science ®Google Scholar
• ArmstrongDKBundyBWenzelLIntraperitoneal cisplatin and paclitaxel in ovarian cancerN Engl J Med20063541344316394300
   PubMed Web of Science ®Google Scholar
• BookmanMABradyMFMcGuireWPEvaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer IntergroupJ Clin Oncol20092791419142519224846
   PubMed Web of Science ®Google Scholar
• BurgerRABradyMFBookmanMAIncorporation of bevacizumab in the primary treatment of ovarian cancerN Engl J Med2011365262473248322204724
   PubMed Web of Science ®Google Scholar
• CohnDEKimKHResnickKEO’MalleyDMStraughnJMJrAt what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysisJ Clin Oncol201129101247125121383297
   PubMed Web of Science ®Google Scholar
• PerrenTJSwartAMPfistererJA Phase 3 trial of bevacizumab in ovarian cancerN Engl J Med2011365262484249622204725
   PubMed Web of Science ®Google Scholar
• BristowRESantillanASalaniRIntraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysisGynecol Oncol2007106347648117688927
   PubMed Web of Science ®Google Scholar
• HavrileskyLJSecordAADarcyKMArmstrongDKKulasingamSCost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol200826254144415018757328
   PubMed Web of Science ®Google Scholar
• WalkerJLIntraperitoneal chemotherapy for ovarian cancer: 2009 goalsGynecol Oncol2009112343944019245944
   PubMed Web of Science ®Google Scholar
• KonnerJSchilderRJDeRosaFAA Phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancerGynecol Oncol2008110214014518554700
   PubMed Web of Science ®Google Scholar
• VaseyPAGoreMWilsonRA Phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancersBr J Cancer200898111774178018506181
   PubMed Web of Science ®Google Scholar
• MarkmanMLiuPYWilczynskiSPhase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trialJ Clin Oncol200321132460246512829663
   PubMed Web of Science ®Google Scholar
• MarkmanMLiuPYMoonJImpact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group Phase 3 trialGynecol Oncol2009114219519819447479
   PubMed Web of Science ®Google Scholar
• PecorelliSFavalliGGadducciAPhase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1J Clin Oncol200927284642464819704064
   PubMed Web of Science ®Google Scholar
• MannelRSBradyMFKohnECA randomized Phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group StudyGynecol Oncol20111221899421529904
   PubMed Web of Science ®Google Scholar
• BerekJTaylorPMcGuireWSmithLMSchultesBNicodemusCFOregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancerJ Clin Oncol200927341842519075271
   PubMed Web of Science ®Google Scholar
• SabbatiniPSillMWO’MalleyDAdlerLSecordAAA Phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group StudyGynecol Oncol2008111345546018829087
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineEfficacy and safety of pazopanib monotherapy after first line chemotherapy in ovarian, fallopian tube, or primary peritoneal cancer2009 Available from: http://www.clinicaltrials.gov/ct2/show/NCT00866697. Accessed April 4, 2012
   Google Scholar